Duloxetine (Cymbalta)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dysthymic Disorder
Conditions
Dysthymic Disorder, Depressive Disorder NOS
Trial Timeline
Aug 1, 2006 → Dec 1, 2013
NCT ID
NCT00360724About Duloxetine (Cymbalta)
Duloxetine (Cymbalta) is a approved stage product being developed by Eli Lilly for Dysthymic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00360724. Target conditions include Dysthymic Disorder, Depressive Disorder NOS.
What happened to similar drugs?
1 of 1 similar drugs in Dysthymic Disorder were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00360724 | Approved | Completed |
Competing Products
1 competing product in Dysthymic Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Desvenlafaxine + Placebo | Pfizer | Approved | 43 |